Mitsubishi UFJ Trust & Banking Corp Has $12.75 Million Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Mitsubishi UFJ Trust & Banking Corp grew its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 15.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 578,265 shares of the company’s stock after purchasing an additional 75,982 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned approximately 0.05% of Teva Pharmaceutical Industries worth $12,745,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the stock. Clal Insurance Enterprises Holdings Ltd lifted its holdings in Teva Pharmaceutical Industries by 12.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company’s stock valued at $859,935,000 after purchasing an additional 4,418,961 shares during the last quarter. Lingotto Investment Management LLP raised its stake in shares of Teva Pharmaceutical Industries by 2.6% in the fourth quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company’s stock valued at $599,320,000 after acquiring an additional 688,862 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its position in Teva Pharmaceutical Industries by 2.2% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company’s stock worth $573,822,000 after acquiring an additional 569,412 shares during the last quarter. State Street Corp grew its position in Teva Pharmaceutical Industries by 10.0% during the 3rd quarter. State Street Corp now owns 19,500,683 shares of the company’s stock worth $351,402,000 after acquiring an additional 1,778,268 shares during the last quarter. Finally, AustralianSuper Pty Ltd increased its holdings in Teva Pharmaceutical Industries by 16.8% during the 4th quarter. AustralianSuper Pty Ltd now owns 9,222,695 shares of the company’s stock valued at $203,268,000 after purchasing an additional 1,329,319 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Trading Down 2.8 %

Shares of NYSE TEVA opened at $15.06 on Friday. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.51 and a fifty-two week high of $22.80. The firm has a market capitalization of $17.07 billion, a P/E ratio of -10.38, a P/E/G ratio of 1.44 and a beta of 0.82. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The company’s 50 day simple moving average is $17.21 and its 200 day simple moving average is $18.12.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on TEVA. Bank of America decreased their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. Piper Sandler increased their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. UBS Group dropped their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. StockNews.com cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Thursday. Finally, Barclays lowered their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $23.43.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.